Antipruritic Market Forecast by Psoriasis and Atopic Dermatitis from 2024 to 2034

<p>The global <strong>antipruritic market </strong>size is projected to surpass a valuation of US$ 16.2 billion by 2034. Our healthcare analysts opine that antipruritic manufacturers can expect a CAGR of 4.2% through 2034, with a current valuation of US$ 10.9 billion in 2024.</p><table><tbody><tr><th scope='row'>Attributes</th><td>Market Insights</td></tr><tr><th scope='row'>Market Value 2023</th><td>US$ 10.5 billion</td></tr><tr><th scope='row'>Market Value 2024</th><td>US$ 10.9 billion</td></tr><tr><th scope='row'>Market Value 2034</th><td>US$ 16.2 billion</td></tr><tr><th scope='row'>CAGR 2024 to 2034</th><td>4.2%</td></tr><tr><th scope='row'>Market Share of Top 5 Countries</th><td>60.8%</td></tr></tbody></table><p>Historical Performance of Antipruritic Market (2019 to 2023) Vs. Forecast Outlook (2024 to 2034)</p><table><tbody><tr><th scope='row'>Attributes</th><td>Details</td></tr><tr><th scope='row'>Antipruritic Market Size (2019)</th><td>US$ 9.1 billion</td></tr><tr><th scope='row'>Antipruritic Market Size (2023)</th><td>US$ 10.5 billion</td></tr><tr><th scope='row'>Antipruritic Market CAGR (2019 to 2023)</th><td>4.1%</td></tr></tbody></table><p>Country-wise Insights</p><table><tbody><tr><th scope='row'>Countries</th><td>CAGR (2024 to 2034)</td></tr><tr><th scope='row'>United States</th><td>37.4%</td></tr><tr><th scope='row'>China</th><td>8.9%</td></tr><tr><th scope='row'>Germany</th><td>4.70%</td></tr><tr><th scope='row'>United Kingdom</th><td>5.10%</td></tr><tr><th scope='row'>Japan</th><td>3.20%</td></tr></tbody></table><p>Category-wise Insights</p><table><tbody><tr><th scope='row'>Segment</th><td>Immunosuppressants (Drug Type)</td></tr><tr><th scope='row'>Value Share (2024)</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>Segment</th><td>Psoriasis (Disease Type)</td></tr><tr><th scope='row'>Value Share (2024)</th><td>33.2%</td></tr></tbody></table><table><tbody><tr><th scope='row'>Segment</th><td>Oral (Route of Administration)</td></tr><tr><th scope='row'>Value Share (2024)</th><td>39.8%</td></tr></tbody></table><table><tbody><tr><th scope='row'>Segment</th><td>Hospital Pharmacies (Distribution Channel)</td></tr><tr><th scope='row'>Value Share (2024)</th><td>30.4%</td></tr></tbody></table>

<p>全球抗瘙痒市场预计到2034年将突破162亿美元的价值评估。我方医疗保健分析师认为，抗瘙痒制造商有望在2034年之前实现4.2%的复合年增长率，目前2024年的价值评估为109亿美元。</p><table><tbody><tr><th scope='row'>属性</th><td>市场洞察</td></tr><tr><th scope='row'>2023年市场价值</th><td>105亿美元</td></tr><tr><th scope='row'>2024年市场价值</th><td>109亿美元</td></tr><tr><th scope='row'>2034年市场价值</th><td>162亿美元</td></tr><tr><th scope='row'>2024至2034年复合年增长率</th><td>4.2%</td></tr><tr><th scope='row'>前五国市场份额</th><td>60.8%</td></tr></tbody></table><p>抗瘙痒市场历史表现（2019至2023年）与预测展望（2024至2034年）</p><table><tbody><tr><th scope='row'>属性</th><td>详情</td></tr><tr><th scope='row'>2019年抗瘙痒市场规模</th><td>91亿美元</td></tr><tr><th scope='row'>2023年抗瘙痒市场规模</th><td>105亿美元</td></tr><tr><th scope='row'>2019至2023年抗瘙痒市场复合年增长率</th><td>4.1%</td></tr></tbody></table><p>各国市场洞察</p><table><tbody><tr><th scope='row'>国家</th><td>2024至2034年复合年增长率</td></tr><tr><th scope='row'>美国</th><td>37.4%</td></tr><tr><th scope='row'>中国</th><td>8.9%</td></tr><tr><th scope='row'>德国</th><td>4.70%</td></tr><tr><th scope='row'>英国</th><td>5.10%</td></tr><tr><th scope='row'>日本</th><td>3.20%</td></tr></tbody></table><p>按类别洞察</p><table><tbody><tr><th scope='row'>类别</th><td>免疫抑制剂（药物类型）</td></tr><tr><th scope='row'>2024年价值占比</th><td>31.3%</td></tr></tbody></table><table><tbody><tr><th scope='row'>类别</th><td>银屑病（疾病类型）</td></tr><tr><th scope='row'>2024年价值占比</th><td>33.2%</td></tr></tbody></table><table><tbody><tr><th scope='row'>类别</th><td>口服（给药途径）</td></tr><tr><th scope='row'>2024年价值占比</th><td>39.8%</td></tr></tbody></table><table><tbody><tr><th scope='row'>类别</th><td>医院药房（分销渠道）</td></tr><tr><th scope='row'>2024年价值占比</th><td>30.4%</td></tr></tbody></table>